Cidara Therapeutics, Inc. - CDTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | BCLS Fund III Investments, LP | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Point72 Asset Management, L.P. | 1.4% | 450,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Point72 Capital Advisors, Inc. | 1.4% | 450,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Steven A. Cohen | 1.4% | 450,000 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Fund Holdings, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity, LLC | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Cayman Fund, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Vivo Opportunity Cayman, LLC | 0.0% | 0 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 6.38% | 2,007,193 | View |
| Jan 09, 2026 | SCHEDULE 13D/A | — | — | — | View |
| Nov 17, 2025 | SCHEDULE 13D/A | — | 9.99% | — | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Commodore Capital LP | 2.0% | 585,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Commodore Capital Master LP | 2.0% | 585,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Robert Egen Atkinson | 2.0% | 585,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Michael Kramarz | 2.0% | 585,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 3.3% | 961,164 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 3.3% | 961,164 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 3.3% | 961,164 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 2.9% | 848,515 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Point72 Asset Management, L.P. | 6.2% | 1,578,069 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Point72 Capital Advisors, Inc. | 6.2% | 1,578,069 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Steven A. Cohen | 6.2% | 1,578,069 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BCLS Fund III Investments, LP | 9.99% | 3,020,990 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | TCG Crossover GP II, LLC | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | TCG Crossover Fund II, L.P. | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Chen Yu | 0.0% | 0 | View |
| Nov 10, 2025 | SCHEDULE 13D/A | — | 9.99% | — | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 2.3% | 635,200 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF I GP LLC | 2.3% | 635,200 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 1.7% | 461,474 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF II GP LLC | 1.7% | 461,474 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.3% | 73,866 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.3% | 73,866 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 4.0% | 1,096,674 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 4.4% | 1,189,165 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF INC/IL | 4.4% | 1,189,165 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | LAMPERT MARK N | 4.4% | 1,189,165 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 2.7% | 729,856 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF I GP LLC | 2.7% | 729,856 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.1% | 578,633 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF II GP LLC | 2.1% | 578,633 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.3% | 77,407 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.3% | 77,407 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 4.8% | 1,308,489 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 5.2% | 1,414,165 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BVF INC/IL | 5.2% | 1,414,165 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | LAMPERT MARK N | 5.2% | 1,414,165 | View |
| Oct 17, 2025 | SCHEDULE 13G/A | BlackRock, Inc. | 4.6% | 1,163,607 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.